查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006423

生物银行市场：2026-2032年全球市场预测（按服务类型、生物样本库类型、检体类型、应用程式和最终用户划分）

Biobanking Market by Offering, Biobank Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物银行市场价值将达到 813.7 亿美元，到 2026 年将成长至 908.6 亿美元，到 2032 年将达到 1820.3 亿美元，复合年增长率为 12.19%。

主要市场统计数据
基准年 2025 813.7亿美元
预计年份：2026年 908.6亿美元
预测年份 2032 1820.3亿美元
复合年增长率 (%) 12.19%

一个创新的生物银行平台正在推动全球科学界在疾病研究和个人化医疗领域取得突破。

生物样本库已成为现代生命科学研究的基础基础设施，它不仅保存了珍贵的生物检体，还能同时收集相关关键数据。随着精准医疗的应用范围不断扩大，研究人员越来越依赖管理完善的检体库来深入了解疾病机制和治疗反应。检体完整性和资料品质之间的这种共生关係凸显了建构稳健的生物银行系统的战略重要性，这类系统需要将先进的保存技术与全面的资讯科学能力无缝整合。

模式转移正在推动生物银行从传统的储存设施向整合的、数据驱动的平台发展，这将塑造未来的研究。

过去十年，创新为生物银行带来了许多变革。最初，重点在于实体储存基础设施，但如今，为了提升效率和扩充性，人们正在采用一套整合技术生态系统。自动化检体搜寻系统减少了人工操作错误，而人工智慧驱动的分析也开始揭示检体利用模式，有助于策略决策。

2025 年美国关税调整评估：不断扩大的成本结构和供应链趋势对生物银行营运和全球合作模式的影响。

随着全球供应链因美国提案的2025年关税调整而重组，生物银行产业面临复杂的挑战与机会。一方面，进口耗材和设备的关税增加可能会推高营运成本，促使相关人员重新评估筹资策略。另一方面，国内生产合作伙伴可能会面临需求激增，这很可能推动本地产能扩张，并促进研究机构与供应商之间建立新的合作关係。

全面的細項分析揭示了生物银行市场的多样化驱动因素，涵盖设备、服务、软体解决方案、检体类型、应用程式和最终用户。

对生物银行产品的分析揭示了其由三个要素构成的结构：有形基础设施、专业服务和数位化管理平台。在产品类型，先进的设备和耗材构成了检体保存的基础。自动化储存系统简化了检体检索流程，低温储存单元则维持着超低温环境。诸如培养箱、离心机、冷藏库和冷冻库等必要的实验室设备与这些核心资产相辅相成，而专门设计的运输和包装单元则在运输过程中保护检体。此外，一系列旨在优化检体活性并符合监管要求的耗材也进一步完善了这些工具。同时，基于服务的模式正在不断发展，以涵盖整体生物银行工作流程。这包括将知情同意和法律规范整合到计划通讯协定中、先进的资料管理和生物资讯解决方案、端到端的检体采集、处理和储存服务，以及确保无缝储存链的专用运输和物流网路。在这些实体和服务元件之上，也建构了一个软体平台，提供集中式监控功能。这使得强大的实验室资讯管理系统和分析仪表板能够汇总元资料，从而支援战略决策。

一份策略性的区域展望报告，重点介绍了美洲、欧洲、中东和非洲以及亚太地区不断扩大的生物银行系统的趋势和成长要素。

在美洲，北美成熟的研究中心持续推动生物银行领域的创新。这些中心拥有先进的设施，并得到雄厚的公共和私人资金支持，充分利用了尖端的低温运输技术和完善的资料管理基础设施。这种成熟的环境促进了学术机构、生技公司和监管机构之间的合作网络，致力于推动精准医疗计画。同时，在拉丁美洲的新兴市场，加强生物样本库能力的投资正在增加，以支持区域人口调查并应对地方性健康挑战。战略伙伴关係和技术转移协议变得至关重要，使相关人员能够在保持全球品质标准的同时，充分利用多样化的本地检体资源。

引领生物银行创新者推动技术创新：透过商业策略和合作专案改变样本储存；分析和物流解决方案。

产业领导企业正透过对自动化、资讯学和策略合作的定向投资，展现出推动生物银行建置的明确决心。例如，一家知名仪器製造商透过整合机器人和云端监控系统，提升了低温储存的自动化程度，实现了即时警报和预测性维护。另一位分子样本製备专家则在其产品组合中新增了一套全面的数据分析解决方案，以优化工作流程并简化监管报告流程。这些技术提供者正在为检体完整性和营运透明度树立新的标竿。

为生物银行相关人员提供的实用蓝图：提高营运效率、促进创新、加强监管合规性、扩大策略伙伴关係。

为了在不断发展的生物银行领域保持竞争优势，产业领导者应优先采用先进的自动化和数数位化技术。将机器人储存和检索系统与集中式分析平台结合，既能提高处理能力，又能最大限度地减少人为错误。此外，整合机器学习工具来预测设备维护需求并简化检体追踪流程，可以增强营运的韧性。

采用稳健的调查方法，结合定性和定量方法；透过一手资料收集和严格的检验过程，确保可靠性和深度。

本报告的调查方法结合了定性和定量方法，旨在提供全面且客观的见解。初步的二手资料研究广泛查阅了学术文献、行业期刊和监管指南，以建立对当前生物银行实践和新兴趋势的基本理解。这项桌上研究有助于发展一手研究的工具和访谈通讯协定。

生物银行发展历程概述：重点在于策略挑战、塑造研究环境的协作创新以及面向未来的解决方案

生物银行领域持续发展，始终是转化研究和精准医疗计画的基石。先进的保存技术、资讯平台和服务导向模式的整合正在重塑传统的工作流程，从而实现更有效率、更可靠的检体管理。此外，虚拟储存库和分散式网路的整合正在拓展合作研究的范围，并促进整个研究界的创新。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物银行市场：依产品/服务分类

  • 产品
    • 生物银行设备
      • 自动化样品储存系统
      • 低温储存系统
      • 培养箱和离心机
      • 冷藏库和冷冻库
      • 检体运送及包装单元
    • 消耗品
  • 服务
    • 同意获取和监管合规服务
    • 资料管理与生物资讯学
    • 检体采集和处理服务
    • 检体储存服务
    • 检体运输及物流
  • 软体

第九章：以生物样本库类型分類的生物银行市场

  • 物理生物样本库
  • 虚拟生物样本库

第十章：检体类型分類的生物银行市场

  • 血
    • 电浆
    • 血清
    • 全血
  • 细胞
  • DNA／RNA
  • 组织

第十一章：生物银行市场：依应用领域划分

  • 诊断和治疗
  • 药物发现与临床研究

第十二章：生物银行市场：依最终使用者划分

  • 学术和研究机构
  • 合约研究组织（CRO）
  • 政府和公共卫生机构
  • 医院/临床检查室
  • 製药和生物技术公司

第十三章：生物银行市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：生物银行市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：生物银行市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物银行市场

第十七章：中国生物银行市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ASKION GmbH
  • Avantor, Inc.
  • Azenta Life Sciences, Inc.
  • BioKryo
  • BioLife Solutions, Inc.
  • Charles River Laboratories International, Inc.
  • Cryoport Systems, LLC
  • Cureline, Inc.
  • FIND
  • Firalis Molecular Precision
  • Greiner Bio-One International GmbH
  • Hamilton Company
  • LGC Biosearch Technologies
  • Merck KGaA
  • PHC Corporation
  • Qiagen NV
  • Sampled
  • Sopachem BV
  • SPT Labtech Ltd
  • STEMCELL Technologies Inc.
  • Taylor-Wharton
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.
  • US Biolab Corporation, Inc.
  • VigiSolvo
Product Code: MRR-961BA04A2DC3

The Biobanking Market was valued at USD 81.37 billion in 2025 and is projected to grow to USD 90.86 billion in 2026, with a CAGR of 12.19%, reaching USD 182.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 81.37 billion
Estimated Year [2026] USD 90.86 billion
Forecast Year [2032] USD 182.03 billion
CAGR (%) 12.19%

Innovative Biobanking Foundations Driving Breakthroughs in Disease Research and Personalized Healthcare Across Global Scientific Communities

Biobanks have emerged as foundational infrastructures in modern life sciences research, preserving precious biological specimens while capturing critical associated data. As the scope of precision medicine expands, researchers increasingly rely on well-curated sample repositories to unlock insights into disease mechanisms and therapeutic responses. This symbiotic relationship between sample integrity and data quality underscores the strategic importance of robust biobanking systems that seamlessly integrate advanced storage technologies with comprehensive informatics capabilities.

In recent years, interdisciplinary collaborations have accelerated innovation across the biobanking landscape. Cutting-edge cryogenic storage platforms now interface with digital management solutions, enabling real-time monitoring of specimen viability and metadata analytics. Consequently, research institutions and industry stakeholders can mitigate variability, enhance reproducibility and accelerate discovery cycles. These technological synergies have redefined best practices, elevating biobanks from passive repositories to dynamic research hubs.

Looking ahead, evolving regulatory frameworks and ethical considerations will further shape the trajectory of biobanking operations. With an emphasis on consent management, data privacy and interoperability standards, biobanks are poised to become pivotal enablers of decentralized clinical trials and population-scale studies. This introductory overview sets the stage for a deeper exploration of the transformative trends driving the next frontier of biobanking excellence.

Global health initiatives are increasingly leveraging biobanking networks to support large-scale population studies and accelerate responses to public health crises. By integrating multi-omic datasets with patient demographics, researchers can identify biomarkers and therapeutic targets with greater precision. Additionally, partnerships between academic consortia, healthcare providers and private sector innovators have intensified, fostering knowledge exchange and accelerating translational pipelines. Consequently, the role of biobanks extends beyond preservation; they are now instrumental in orchestrating collaborative research efforts that span continents and disciplines, ultimately contributing to more resilient healthcare systems and improved patient outcomes.

Paradigm Shifts Catalyzing the Evolution of Biobanking from Conventional Storage Facilities to Integrated Data-Driven Platforms Shaping Future Research

Innovation has propelled biobanking through several transformative shifts over the last decade. Initially focused on physical storage infrastructure, the discipline now embraces an ecosystem of integrated technologies that promote efficiency and scalability. Automated sample retrieval systems have reduced manual handling errors, while artificial intelligence-driven analytics have begun to uncover patterns in specimen utilization that inform strategic decision making.

Moreover, the rise of virtual biobanks has redefined traditional paradigms by enabling remote access to digital representations of biological materials. This shift has fostered cross-institutional collaborations, as researchers can now query standardized datasets without logistical constraints. Simultaneously, the emergence of cloud-based platforms has facilitated streamlined data governance, providing secure channels for consent management and multi-modal integration of genomic, clinical and environmental data.

In addition, service-oriented models have gained prominence, with specialized providers offering end-to-end solutions spanning sample collection, processing, storage and transport. This diversification has allowed organizations to tailor biobanking strategies to project-specific requirements, optimizing resource allocation and reducing time to insight. As the biobanking sector continues to mature, these foundational shifts will underpin future innovations and guide sustainable growth across the global research landscape.

Emerging trends in sustainability and environmental responsibility are also reshaping biobanking practices. Institutions are adopting energy-efficient ultra-low temperature freezers and exploring renewable energy integration within cold storage facilities to minimize carbon footprints. In parallel, digital twin models of storage environments enable simulation of energy usage patterns to optimize resource allocation. As a result, biobanks are not only improving operational efficiency but also aligning with corporate social responsibility goals, reinforcing their commitment to sustainable science and long-term viability in a resource-conscious world.

Assessment of United States Tariff Adjustments in 2025 Expanding Cost Structures and Supply Chain Dynamics Impacting Biobanking Operations and Global Collaboration Models

As global supply chains recalibrate in response to the United States' proposed 2025 tariff adjustments, the biobanking community faces a complex set of challenges and opportunities. On one hand, increased duties on imported consumables and equipment could elevate operational costs, prompting stakeholders to reevaluate procurement strategies. On the other hand, domestic manufacturing partners may experience a surge in demand, driving expansion of local production capabilities and fostering new alliances between research institutions and suppliers.

Furthermore, shifting trade policies have underscored the importance of supply chain resilience. In response, biobanks are diversifying vendor portfolios and exploring nearshoring options to mitigate the risk of prolonged lead times and geopolitical disruptions. At the same time, strategic stockpiling of critical reagents and consumables has emerged as a proactive measure to ensure continuity of operations, particularly for long-term cohort studies and high-throughput variant screening projects.

In addition to cost implications, regulatory harmonization efforts are gaining momentum. Collaborative dialogues between public health agencies and industry consortia aim to streamline cross-border logistics, reduce documentation burdens and expedite customs clearance processes. Consequently, the sector can maintain high standards of sample integrity while adapting to evolving trade environments. Taken together, these dynamics will redefine procurement frameworks and operational priorities across the biobanking value chain.

As organizations navigate these tariff-induced cost pressures, many are exploring performance-based contracts with suppliers to achieve negotiated pricing and guarantee supply continuity. Simultaneously, government incentive programs and public-private funding initiatives aim to offset increased duties, offering grants and tax credits for domestic equipment investments. These support mechanisms foster local manufacturing expansion and encourage stakeholders to engage in long-term infrastructure planning.

Comprehensive Segmentation Insights Revealing Diverse Biobanking Market Drivers Spanning Equipment, Services, Software Solutions, Specimen Types, Applications and End Users

An examination of biobanking offerings reveals a tripartite structure encompassing tangible infrastructure, specialized services and digital management platforms. Within the product category, sophisticated equipment and consumables form the backbone of specimen preservation. Automated storage systems streamline sample retrieval while cryogenic storage units maintain ultra-low temperature integrity. Essential laboratory instruments such as incubators, centrifuges, refrigerators and freezers complement these core assets, and purpose-designed transport and packaging units safeguard specimens during transit. Complementing these tools is an array of consumables engineered for optimal sample viability and regulatory compliance. Meanwhile, service-based models have evolved to address the full spectrum of biobanking workflows: consent and regulatory frameworks embedded within project protocols; advanced data management and bioinformatics solutions; end-to-end sample collection, processing and storage services; and dedicated transport and logistics networks that ensure seamless chain of custody. Layered atop these physical and service components, software platforms provide centralized oversight, offering robust laboratory information management systems and analytical dashboards that aggregate metadata to inform strategic decisions.

Diving deeper into biobank typologies, traditional physical repositories coexist with emerging virtual environments. The former emphasizes on-site specimen curation and long-term archiving, whereas the latter leverages digital interfaces and distributed data links to facilitate remote access and collaborative research. This dual approach enables institutions to adapt storage strategies to project demands, balancing in-house capabilities with networked sharing models.

Regarding specimen categories, whole blood and its derivatives-plasma and serum-form a critical segment, alongside discrete cell lines, extracted DNA and RNA preparations, and a diverse array of tissue samples. Each sample type presents unique handling and preservation challenges, driving tailored protocol development.

In terms of application, biobanks support both diagnostics and therapeutics through patient specimen repositories and serve as foundational resources for drug discovery and clinical research initiatives. This breadth of use cases underscores the sector's capacity to bridge translational gaps.

Finally, a wide spectrum of end users relies on these segmented offerings. Academic and research institutions pursue foundational science, whereas contract research organizations prioritize streamlined trial operations. Government and public health agencies demand stringent compliance, clinical laboratories and hospital systems integrate repositories into care pathways, and pharmaceutical and biotechnology companies harness biobanking assets to accelerate pipeline development.

Strategic Regional Perspectives Highlighting Trends and Growth Levers Across Americas, Europe Middle East Africa and Asia-Pacific in the Expanding Biobanking Ecosystem

Throughout the Americas, established research hubs in North America continue to drive innovation in biobanking. Cutting-edge facilities leverage state-of-the-art cold chain technologies and comprehensive data management infrastructures, underpinned by robust funding from public and private sources. This mature environment fosters collaborative networks between academic centers, biotechnology firms and regulatory bodies focused on advancing precision medicine initiatives. At the same time, emerging markets in Latin America are increasingly investing in biobank capabilities to support regional population studies and address endemic health challenges. As a result, strategic partnerships and technology transfer agreements have become pivotal, enabling stakeholders to capitalize on local sample diversity while maintaining global quality standards.

In Europe, Middle East and Africa, a diverse mosaic of biobanking ecosystems is taking shape. European nations benefit from pan-national consortia that harmonize protocols, data privacy regulations and operational benchmarks, creating scalable repositories accessible to multinational research teams. Meanwhile, several Middle Eastern countries are bolstering infrastructure investments to advance national genomics agendas and public health surveillance. Across Africa, partnerships with international research organizations are catalyzing the development of population-scale biobanks aimed at understanding disease dynamics within underrepresented cohorts. Despite challenges related to funding models and logistic complexities, this region presents significant opportunities for collaborative innovation and capacity building.

Asia-Pacific exhibits rapid expansion driven by government-led precision health programs and a burgeoning biotechnology sector. Leading economies such as China, Japan and Australia have established sophisticated biobank networks integrated with hospital systems and research institutes, reinforcing translational research pipelines. In parallel, India and Southeast Asian nations are scaling sample collection and processing capabilities to support large-scale cohort studies. Stakeholders in this region are prioritizing regulatory harmonization, digital transformation of laboratory workflows and localized manufacturing of critical consumables. Consequently, Asia-Pacific is poised to become a strategic growth arena, shaping global biobanking trends and best practices.

Leading Biobanking Innovators Driving Technological Advancements Commercial Strategies and Collaborative Ventures Transforming Sample Storage Analytical and Logistics Solutions

Industry leaders have demonstrated a clear commitment to advancing biobanking through targeted investments in automation, informatics and strategic collaborations. For instance, one prominent instrumentation provider has enhanced cryogenic storage automation by integrating robotics with cloud-based monitoring systems, enabling real-time alerts and predictive maintenance. Another specialist in molecular sample preparation has expanded its portfolio to include comprehensive data analytics solutions that streamline workflow optimization and regulatory reporting. These technology providers are setting new standards for specimen integrity and operational transparency.

Meanwhile, a leading automation firm has deployed high-throughput liquid handling platforms capable of processing thousands of samples per day, reducing manual intervention and accelerating study timelines. An established laboratory systems supplier has fortified its software suite, embedding laboratory information management functionalities that support chain-of-custody tracking, consent management and multi-site collaboration. Complementing these efforts, several emerging biotech companies are focusing on modular cold chain consumables designed to maintain ultra-low temperature stability during long-distance shipments.

Additionally, several agile startups are challenging incumbent players by developing niche solutions such as lab-on-chip sample stabilization and blockchain-based provenance tracking. These disruptive entrants emphasize modularity and interoperability, compelling established companies to accelerate innovation cycles and integrate open-architecture frameworks. This dynamic competitive landscape underscores the value of continuous R&D investments and adaptive business models.

Moreover, strategic partnerships and mergers have reshaped the competitive landscape. Major corporations have acquired niche informatics firms to bolster their end-to-end biobanking offerings, while others have forged alliances with academic consortia to pilot decentralized storage models. These corporate maneuvers underscore a broader trend toward integrated solutions designed to address the diverse needs of research institutions, clinical laboratories and pharmaceutical developers alike.

Actionable Roadmap for Biobanking Stakeholders to Enhance Operational Efficiency Foster Innovation Strengthen Regulatory Compliance and Expand Strategic Collaborations

To maintain a competitive edge in the evolving biobanking arena, industry leaders should prioritize the adoption of advanced automation and digitalization technologies. Implementing robotic storage and retrieval systems, coupled with centralized analytics platforms, can enhance throughput while minimizing human error. In addition, integrating machine learning tools to predict equipment maintenance and streamline sample tracking will reinforce operational resilience.

Concurrently, organizations must reinforce their regulatory and ethical frameworks by establishing transparent consent management processes and adhering to emerging international standards. Developing modular compliance protocols that can be adapted to new jurisdictions will reduce administrative overhead and facilitate cross-border research collaborations.

Fostering partnerships across research institutions, service providers and technology vendors will unlock synergies and accelerate innovation. Joint ventures and consortia can pool resources for large-scale studies, enabling access to diverse specimen collections and sharing best practices in specimen handling and data governance.

Furthermore, procurement strategies should emphasize supply chain diversification and local sourcing of critical equipment and consumables. By cultivating relationships with multiple vendors and exploring nearshoring options, biobanking operations can mitigate the impact of tariff fluctuations and logistical disruptions.

Prioritizing robust cybersecurity measures and data interoperability standards is equally important. Biobanking leaders should establish encrypted data exchanges and adopt universal metadata schemas to facilitate seamless collaboration. This emphasis on secure and harmonized data flows will further strengthen trust among partners and enhance the scalability of cross-institutional research programs.

Finally, continuous skills development remains vital. Investing in targeted training programs for technical staff and data managers will ensure that organizations can effectively leverage new technologies and maintain high standards of sample integrity and data quality.

Robust Research Methodology Integrating Qualitative and Quantitative Approaches Primary Data Collection and Rigorous Validation Processes Ensuring Reliability and Depth

The research methodology underpinning this report combines both qualitative and quantitative approaches to deliver comprehensive and unbiased insights. Initial secondary research involved an extensive review of academic literature, industry publications and regulatory guidelines to establish a foundational understanding of current biobanking practices and emerging trends. This desk research informed the development of primary research instruments and interview protocols.

Primary data collection was conducted through in-depth interviews with leading practitioners, equipment manufacturers, service providers and regulatory experts. These discussions provided nuanced perspectives on operational challenges, technology adoption and strategic priorities. In parallel, an online survey targeted a broad cross-section of end users to capture quantitative data on sample type preferences, storage requirements and budgetary allocations.

Data triangulation was achieved by cross-verifying information from multiple sources, ensuring that findings reflect a consistent and accurate industry narrative. Key metrics and thematic insights were validated through iterative expert reviews, enabling adjustments to interpretation and emphasis based on peer feedback. Statistical analysis techniques, including trend mapping and correlation assessments, further enriched the robustness of the conclusions.

The research methodology also incorporated a thorough review of ethical frameworks and data privacy regulations. Potential limitations related to respondent bias and geographic representation were mitigated through purposive sampling and weighting adjustments. Ethical considerations guided the design of interview questions and data handling protocols, ensuring anonymity and compliance with global human subject research standards.

Overall, the methodology was designed to balance depth and breadth, combining granular field-level observations with high-level trend analysis. This hybrid approach ensures that the resulting strategic recommendations and market insights are both actionable and grounded in empirical evidence.

Concluding Reflections on Biobanking Evolution Emphasizing Strategic Imperatives Collaborative Innovations and Future-Ready Solutions Shaping the Research Landscape

As the biobanking sector continues to evolve, it remains a cornerstone of translational research and precision medicine endeavors. The convergence of advanced storage technologies, informatics platforms and service-oriented models has reshaped traditional workflows, enabling more efficient and reliable specimen management. Moreover, the integration of virtual repositories and decentralized networks has expanded collaborative horizons, fostering innovation across research communities.

Regulatory realignments and tariff dynamics further underscore the need for agile operational strategies. By embracing diversified procurement configurations and strengthening cross-border logistics frameworks, organizations can safeguard supply continuity and maintain high standards of sample viability. Meanwhile, segmentation insights reveal that a comprehensive understanding of product offerings, biobank typologies, specimen categories, application areas and end-user needs is essential for designing tailored solutions that drive scientific progress.

Regional analysis highlights distinct geographical opportunities, from established hubs in North America and Europe to rapidly emerging markets in Asia-Pacific and strategic growth corridors across the Middle East and Africa. Concurrently, leading companies are demonstrating how targeted investments in automation, analytics and strategic partnerships can unlock new value propositions.

Ultimately, thriving biobanking ecosystems will depend on continuous innovation, inclusive governance structures and adaptive business models. Collaborative innovation hubs and public-private consortia will play pivotal roles in translating scientific discoveries into scalable solutions. Embracing a culture of transparency, shared learning and technological agility will be key to sustaining momentum as the field advances.

Looking forward, the path to sustainable biobanking excellence will hinge on balancing operational efficiency with ethical governance, fostering collaborative ecosystems and continuously innovating through technology adoption. These strategic imperatives offer a clear roadmap for stakeholders seeking to advance research capabilities and deliver impactful outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biobanking Market, by Offering

  • 8.1. Product
    • 8.1.1. Biobanking Equipment
      • 8.1.1.1. Automated Sample Storage Systems
      • 8.1.1.2. Cryogenic Storage Systems
      • 8.1.1.3. Incubators & Centrifuges
      • 8.1.1.4. Refrigerators & Freezers
      • 8.1.1.5. Sample Transport & Packaging Units
    • 8.1.2. Consumables
  • 8.2. Services
    • 8.2.1. Consent & Regulatory Compliance Services
    • 8.2.2. Data Management & Bioinformatics
    • 8.2.3. Sample Collection & Processing Services
    • 8.2.4. Sample Storage Services
    • 8.2.5. Sample Transport & Logistics
  • 8.3. Software

9. Biobanking Market, by Biobank Type

  • 9.1. Physical Biobanks
  • 9.2. Virtual Biobanks

10. Biobanking Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
    • 10.1.3. Whole Blood
  • 10.2. Cells
  • 10.3. DNA/RNA
  • 10.4. Tissue

11. Biobanking Market, by Application

  • 11.1. Diagnostics & Therapeutics
  • 11.2. Drug Discovery & Clinical Research

12. Biobanking Market, by End User

  • 12.1. Academic & Research Institutions
  • 12.2. Contract Research Organizations (CROs)
  • 12.3. Government & Public Health Agencies
  • 12.4. Hospitals & Clinical Labs
  • 12.5. Pharmaceutical & Biotech Companies

13. Biobanking Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biobanking Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biobanking Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biobanking Market

17. China Biobanking Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ASKION GmbH
  • 18.6. Avantor, Inc.
  • 18.7. Azenta Life Sciences, Inc.
  • 18.8. BioKryo
  • 18.9. BioLife Solutions, Inc.
  • 18.10. Charles River Laboratories International, Inc.
  • 18.11. Cryoport Systems, LLC
  • 18.12. Cureline, Inc.
  • 18.13. FIND
  • 18.14. Firalis Molecular Precision
  • 18.15. Greiner Bio-One International GmbH
  • 18.16. Hamilton Company
  • 18.17. LGC Biosearch Technologies
  • 18.18. Merck KGaA
  • 18.19. PHC Corporation
  • 18.20. Qiagen N.V.
  • 18.21. Sampled
  • 18.22. Sopachem BV
  • 18.23. SPT Labtech Ltd
  • 18.24. STEMCELL Technologies Inc.
  • 18.25. Taylor-Wharton
  • 18.26. Tecan Trading AG
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. US Biolab Corporation, Inc.
  • 18.29. VigiSolvo

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOBANKING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOBANKING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOBANKING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOBANKING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOBANKING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOBANKING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOBANKING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOBANKING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOBANKING MARKET SIZE, BY PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOBANKING MARKET SIZE, BY PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOBANKING MARKET SIZE, BY PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOBANKING MARKET SIZE, BY AUTOMATED SAMPLE STORAGE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOBANKING MARKET SIZE, BY AUTOMATED SAMPLE STORAGE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOBANKING MARKET SIZE, BY AUTOMATED SAMPLE STORAGE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOBANKING MARKET SIZE, BY CRYOGENIC STORAGE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOBANKING MARKET SIZE, BY CRYOGENIC STORAGE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOBANKING MARKET SIZE, BY CRYOGENIC STORAGE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOBANKING MARKET SIZE, BY INCUBATORS & CENTRIFUGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOBANKING MARKET SIZE, BY INCUBATORS & CENTRIFUGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOBANKING MARKET SIZE, BY INCUBATORS & CENTRIFUGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOBANKING MARKET SIZE, BY REFRIGERATORS & FREEZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOBANKING MARKET SIZE, BY REFRIGERATORS & FREEZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOBANKING MARKET SIZE, BY REFRIGERATORS & FREEZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & PACKAGING UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & PACKAGING UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & PACKAGING UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOBANKING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOBANKING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOBANKING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOBANKING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOBANKING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOBANKING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOBANKING MARKET SIZE, BY CONSENT & REGULATORY COMPLIANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOBANKING MARKET SIZE, BY CONSENT & REGULATORY COMPLIANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOBANKING MARKET SIZE, BY CONSENT & REGULATORY COMPLIANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOBANKING MARKET SIZE, BY DATA MANAGEMENT & BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOBANKING MARKET SIZE, BY DATA MANAGEMENT & BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOBANKING MARKET SIZE, BY DATA MANAGEMENT & BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE COLLECTION & PROCESSING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE COLLECTION & PROCESSING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE COLLECTION & PROCESSING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE STORAGE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE STORAGE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE STORAGE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & LOGISTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & LOGISTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & LOGISTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOBANKING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOBANKING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOBANKING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOBANKING MARKET SIZE, BY PHYSICAL BIOBANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOBANKING MARKET SIZE, BY PHYSICAL BIOBANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOBANKING MARKET SIZE, BY PHYSICAL BIOBANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOBANKING MARKET SIZE, BY VIRTUAL BIOBANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOBANKING MARKET SIZE, BY VIRTUAL BIOBANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOBANKING MARKET SIZE, BY VIRTUAL BIOBANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOBANKING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOBANKING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOBANKING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOBANKING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOBANKING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOBANKING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOBANKING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOBANKING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOBANKING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOBANKING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOBANKING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOBANKING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOBANKING MARKET SIZE, BY CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOBANKING MARKET SIZE, BY CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOBANKING MARKET SIZE, BY CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOBANKING MARKET SIZE, BY DNA/RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOBANKING MARKET SIZE, BY DNA/RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOBANKING MARKET SIZE, BY DNA/RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOBANKING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOBANKING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOBANKING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOBANKING MARKET SIZE, BY DIAGNOSTICS & THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOBANKING MARKET SIZE, BY DIAGNOSTICS & THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOBANKING MARKET SIZE, BY DIAGNOSTICS & THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOBANKING MARKET SIZE, BY DRUG DISCOVERY & CLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOBANKING MARKET SIZE, BY DRUG DISCOVERY & CLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOBANKING MARKET SIZE, BY DRUG DISCOVERY & CLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOBANKING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOBANKING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOBANKING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOBANKING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOBANKING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOBANKING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOBANKING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOBANKING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOBANKING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOBANKING MARKET SIZE, BY HOSPITALS & CLINICAL LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOBANKING MARKET SIZE, BY HOSPITALS & CLINICAL LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOBANKING MARKET SIZE, BY HOSPITALS & CLINICAL LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOBANKING MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOBANKING MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOBANKING MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOBANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 198. GCC BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 199. GCC BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 200. GCC BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. GCC BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 204. GCC BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 228. G7 BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 229. G7 BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 230. G7 BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. G7 BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 238. NATO BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. NATO BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 240. NATO BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)